Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".
Saved in:
| Title: | Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial". |
|---|---|
| Authors: | Nishida N; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan. |
| Source: | Clinical and molecular hepatology [Clin Mol Hepatol] 2025 Jan; Vol. 31 (1), pp. 311-315. Date of Electronic Publication: 2024 Sep 03. |
| Publication Type: | Editorial |
| Journal Info: | Publisher: Korean Association for the Study of the Liver Country of Publication: Korea (South) NLM ID: 101586730 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2287-285X (Electronic) Linking ISSN: 22872728 NLM ISO Abbreviation: Clin Mol Hepatol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
